The global kidney
cancer drugs market size is expected to be valued at USD 6.3
billion by 2022, as per a new report by Grand View Research, Inc., registering
a CAGR of 5.4% during the forecast period. Market growth is largely driven by
factors such as availability of novel drugs and presence of a strong pipeline.
Growth can also be attributed to rise in incidence of renal cancer due to
growing geriatric population and changes in lifestyle such as increased smoking
and intake of alcohol.
In 2012, kidney cancer was the 13th most
prevalent cancer worldwide, accounting for approximately 2.0% of all adult
malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer
cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas.
Various forms of cancer treatment methods have been implemented among the
currently approved drugs, including immune modulation therapy, cytokine
therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF)
inhibitor.
Browse full research report on Kidney Cancer Drugs Market: https://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market
Further
key findings from the report suggest:
- Increasing incidence of the disease and rising geriatric population
globally are amongst major factors stimulating market growth
- Novel agents have expanded market opportunities through larger
number of patients under treatment and better treatment prospects compared
to traditional therapies. The notable clinical profile of immuno-oncology
drugs is reflected their rapid uptake and expansion of indications
- The current treatment landscape in metastatic and advanced RCC will
shift from TKI and mTOR inhibitors to specific immuno-oncology agents like
immune checkpoint inhibitors (ICI), which have demonstrated positive
results on PFS as monotherapy (Opdivo) or combination therapy
(Opdivo+Yervoy)
- U.S. accounted for more than 35.0% of the market in 2016 due to
increasing incidence of renal cell carcinoma and presence of key
manufacturers in the country. On the other hand, surge in kidney cancer
screening is a key driver in markets such as EU
- Emerging markets in Asia Pacific and Middle East and Africa are
fueled by increasing expenditure on healthcare, a large untapped patient
population base due to rise in elderly population, and improvement in
diagnostic technologies
- Some of the key players operating in this market are Pfizer,
Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations
for development, broader product portfolios, and regional expansion in
emerging markets are key strategic undertakings of these companies to
increase market share.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand
View Research has segmented the global kidney cancer drugs market based on
therapeutic class, pharmacologic class, and country:
Kidney
Cancer Drugs Therapeutic Class Outlook (USD Million, 2016 - 2022)
- Targeted
Therapy
- Immunotherapy
Kidney
Cancer Drugs Pharmacologic Class Outlook (USD Million, 2016 - 2022)
- Angiogenesis
Inhibitors
- mTOR
Inhibitors
- Monoclonal
Antibodies
- Cytokine
Immunotherapy (IL-2)
Kidney
Cancer Drugs Country Outlook (USD Million, 2016 - 2022)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment